D. Scott Neal Inc. Acquires 1,857 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

D. Scott Neal Inc. boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.6% during the second quarter, HoldingsChannel reports. The fund owned 34,808 shares of the medical research company’s stock after buying an additional 1,857 shares during the period. Charles River Laboratories International comprises 4.0% of D. Scott Neal Inc.’s holdings, making the stock its 8th biggest position. D. Scott Neal Inc.’s holdings in Charles River Laboratories International were worth $7,191,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $41,000. VisionPoint Advisory Group LLC raised its position in Charles River Laboratories International by 45.1% in the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 65 shares during the period. Brown Brothers Harriman & Co. raised its position in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after purchasing an additional 95 shares during the period. GAMMA Investing LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $62,000. Finally, Concord Wealth Partners raised its position in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after purchasing an additional 203 shares during the period. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CRL shares. Mizuho started coverage on Charles River Laboratories International in a research report on Friday, June 7th. They issued a “neutral” rating and a $235.00 target price on the stock. StockNews.com raised Charles River Laboratories International from a “hold” rating to a “buy” rating in a research report on Thursday. The Goldman Sachs Group cut their target price on Charles River Laboratories International from $290.00 to $250.00 and set a “buy” rating on the stock in a research report on Thursday. JPMorgan Chase & Co. lowered Charles River Laboratories International from an “overweight” rating to a “neutral” rating and cut their target price for the company from $270.00 to $205.00 in a research report on Thursday. Finally, UBS Group cut their price objective on Charles River Laboratories International from $290.00 to $240.00 and set a “buy” rating on the stock in a research report on Thursday. Ten investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $231.00.

Charles River Laboratories International Stock Down 3.3 %

NYSE:CRL traded down $6.62 during trading hours on Monday, hitting $194.35. The company’s stock had a trading volume of 1,539,577 shares, compared to its average volume of 587,541. The stock has a market capitalization of $10.01 billion, a P/E ratio of 22.86, a price-to-earnings-growth ratio of 2.32 and a beta of 1.38. The stock has a fifty day moving average of $214.72 and a 200-day moving average of $231.28. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, equities analysts forecast that Charles River Laboratories International, Inc. will post 10.99 earnings per share for the current year.

Charles River Laboratories International declared that its board has approved a stock repurchase plan on Wednesday, August 7th that allows the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization allows the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).